Liquidia财年Yutrepia初步净销售额达1.483亿美元（修正版：补充遗漏产品名称并删除预估数据）

美股速递01-09

生物制药公司Liquidia Technologies Inc公布其肺动脉高压治疗药物Yutrepia在最新财年实现初步净销售额1.483亿美元。此次披露的数据修正了早前版本中遗漏产品名称及包含预估信息的表述，以更准确反映实际销售表现。

作为公司核心商业化产品，Yutrepia的销售业绩凸显了其在专科治疗领域的市场渗透力。该修正公告旨在确保投资者获得清晰透明的财务信息，同时避免对未经核实的预估数据产生误解。

随着肺动脉高压治疗市场竞争加剧，此次销售额的确认将为市场评估Liquidia Technologies Inc未来增长潜力提供关键依据。公司后续或将基于完整财年审计结果进一步更新财务细节。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1182197366?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-09 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182197366","market":"us","top_or_hot":-1,"title":"Liquidia财年Yutrepia初步净销售额达1.483亿美元（修正版：补充遗漏产品名称并删除预估数据）","media":"美股速递","content":"<p>生物制药公司Liquidia Technologies Inc公布其肺动脉高压治疗药物Yutrepia在最新财年实现初步净销售额1.483亿美元。此次披露的数据修正了早前版本中遗漏产品名称及包含预估信息的表述，以更准确反映实际销售表现。</p>\n<p>作为公司核心商业化产品，Yutrepia的销售业绩凸显了其在专科治疗领域的市场渗透力。该修正公告旨在确保投资者获得清晰透明的财务信息，同时避免对未经核实的预估数据产生误解。</p>\n<p>随着肺动脉高压治疗市场竞争加剧，此次销售额的确认将为市场评估Liquidia Technologies Inc未来增长潜力提供关键依据。公司后续或将基于完整财年审计结果进一步更新财务细节。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia财年Yutrepia初步净销售额达1.483亿美元（修正版：补充遗漏产品名称并删除预估数据）</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia财年Yutrepia初步净销售额达1.483亿美元（修正版：补充遗漏产品名称并删除预估数据）\n</h2>\n\n<h4 class=\"meta\">\n\n2026-01-09 19:55 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物制药公司Liquidia Technologies Inc公布其肺动脉高压治疗药物Yutrepia在最新财年实现初步净销售额1.483亿美元。此次披露的数据修正了早前版本中遗漏产品名称及包含预估信息的表述，以更准确反映实际销售表现。\n作为公司核心商业化产品，Yutrepia的销售业绩凸显了其在专科治疗领域的市场渗透力。该修正公告旨在确保投资者获得清晰透明的财务信息，同时避免对未经核实的预估数据...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"","article_id":"1182197366","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182197366","pubTimestamp":1767959716,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"生物制药公司Liquidia Technologies Inc公布其肺动脉高压治疗药物Yutrepia在最新财年实现初步净销售额1.483亿美元。此次披露的数据修正了早前版本中遗漏产品名称及包含预估信息的表述，以更准确反映实际销售表现。作为公司核心商业化产品，Yutrepia的销售业绩凸显了其在专科治疗领域的市场渗透力。随着肺动脉高压治疗市场竞争加剧，此次销售额的确认将为市场评估Liquidia Technologies Inc未来增长潜力提供关键依据。公司后续或将基于完整财年审计结果进一步更新财务细节。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"Liquidia's preliminary net sales of Yutrepia in fiscal year amounted to $148.3 million (revised version: supplementing missing product names and removing estimates)","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"生物制药公司Liquidia Technologies Inc公布其肺动脉高压治疗药物Yutrepia在最新财年实现初步净销售额1.483亿美元。此次披露的数据修正了早前版本中遗漏产品名称及包含预估信息的表述，以更准确反映实际销售表现。\n作为公司核心商业化产品，Yutrepia的销售业绩凸显了其在专科治疗领域的市场渗透力。该修正公告旨在确保投资者获得清晰透明的财务信息，同时避免对未经核实的预估数据产生误解。\n随着肺动脉高压治疗市场竞争加剧，此次销售额的确认将为市场评估Liquidia Technologies Inc未来增长潜力提供关键依据。公司后续或将基于完整财年审计结果进一步更新财务细节。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182197366","isCrawlerRequest":true}